KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) FCF Margin (2017 - 2025)

Historic FCF Margin for Sarepta Therapeutics (SRPT) over the last 12 years, with Q2 2025 value amounting to 37.56%.

  • Sarepta Therapeutics' FCF Margin rose 414800.0% to 37.56% in Q2 2025 from the same period last year, while for Sep 2025 it was 27.59%, marking a year-over-year increase of 10900.0%. This contributed to the annual value of 18.02% for FY2024, which is 284000.0% up from last year.
  • Per Sarepta Therapeutics' latest filing, its FCF Margin stood at 37.56% for Q2 2025, which was up 414800.0% from 559.9% recorded in Q1 2025.
  • In the past 5 years, Sarepta Therapeutics' FCF Margin registered a high of 37.56% during Q2 2025, and its lowest value of 559.9% during Q1 2025.
  • Over the past 5 years, Sarepta Therapeutics' median FCF Margin value was 41.17% (recorded in 2022), while the average stood at 69.82%.
  • Examining YoY changes over the last 5 years, Sarepta Therapeutics' FCF Margin showed a top increase of 1243200bps in 2021 and a maximum decrease of -6814000bps in 2021.
  • Over the past 5 years, Sarepta Therapeutics' FCF Margin (Quarter) stood at 15.65% in 2021, then tumbled by -148bps to 38.83% in 2022, then soared by 52bps to 18.57% in 2023, then skyrocketed by 144bps to 8.2% in 2024, then soared by 358bps to 37.56% in 2025.
  • Its FCF Margin was 37.56% in Q2 2025, compared to 559.9% in Q1 2025 and 8.2% in Q4 2024.